SALT LAKE CITY, June 6, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled "Prognostic value of a 46-gene cell cycle progression (CCP) RNA ...
SALT LAKE CITY, May 18, 2011 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today the presentation of a study at the American Society of Clinical Oncology® (ASCO) Annual Meeting, ...
SALT LAKE CITY, Utah, May 20, 2014 – Myriad Genetics, Inc. (NASDAQ: MYGN) today presented new data from a clinical validation study of Prolaris at the 2014 American Urological Association (AUA) Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback